1 May 2016 - The May 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of two new medicines.

The new medicines are cinacalcet hydrochloride (Sensipar) and galsulfase (Naglazyme).

Cinacalcet hydrochloride has been listed to use by patients with hypercalcaemia or calciphylaxis.  Sensipar is not registered for use for the latter patient population.

Galsulfase (Naglazyme) has been listed for use by patients with mucopolysaccharosis type VI under Special Authority criteria and in DHB hospitals subject to restrictions.

For more details, go to: http://www.pharmac.govt.nz/2016/04/18/SU.pdf